EUCTR2018-003790-10-FI进行中（未招募）1 期
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix® or NeisVac-C® in Healthy Toddlers 12 to 23 Months of Age
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 705
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Aged 12 to 23 months on the day of the first study visit (12 to 23 months” means from the 12th month after birth to the day before the 24th month after birth)
- •- Informed consent form (ICF) has been signed and dated by the parent(s) / legally acceptable representative(s) and by an independent witness if required by local regulations.
- •- Subject and parent / legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 705
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Participation in the 4 weeks (28 days) preceding the study vaccination or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.
- •- Receipt of any vaccine in the 4 weeks (28 days) preceding the trial vaccination or planned receipt of any vaccine prior to Visit 2 except for influenza vaccination, which may be received at least 2 weeks before or after study vaccines. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines.
- •- Receipt of immune globulins, blood or blood-derived products in the past 3 months.
- •- Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine (i.e., mono- or polyvalent, polysaccharide, or conjugate meningococcal vaccine containing serogroups A, C, W, or Y; or meningococcal B vaccine).
- •- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
- •- History of meningococcal infection, confirmed either clinically, serologically, or microbiologically.
- •- At high risk for meningococcal infection during the trial (specifically, but not limited to, subjects with persistent complement deficiency, with anatomic or functional asplenia, or subjects travelling to countries with high endemic or epidemic disease).
- •- Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances .
- •- Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine.
- •- Personal history of Guillain-Barré syndrome (GBS).
- •- Thrombocytopenia, as reported by the parent/ legally acceptable representative or suspected thrombocytopenia contraindicating intramuscular vaccination in the Investigator’s opinion.
- •- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination in the Investigator’s opinion.
- •- Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion.
- •- Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature = 38.0°C). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided.
- •- Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.
- •- Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study.
研究者
相似试验
进行中（未招募）
1 期
Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in Europeans ToddlersHealthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W)MedDRA version: 20.0Level: PTClassification code 10027274Term: Meningococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-003790-10-DKSanofi Pasteur705
进行中（未招募）
1 期
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered as a Booster Dose in Children Vaccinated 3 Years Earlier as ToddlersHealthy meningococcal vaccine primed male and female children aged 4-5 years who were previously vaccinated 3 years (± 45 days) earlier at 12 to 23 months of age in study MET54EUCTR2017-001993-40-FISanofi Pasteur188
进行中（未招募）
1 期
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers 12 to 23 Months of AgeEUCTR2016-000749-30-DESanofi Pasteur918
进行中（未招募）
1 期
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers 12 to 23 Months of AgeEUCTR2016-000749-30-ESSanofi Pasteur918
招募中
3 期
A clinical study to evaluate immunogenicity and safety of a Meningococcal vaccine in healthy adults, adolescents, and children in India and healthy adolescents and children in the Republic of South AfricaCTRI/2019/10/021535Sanofi Pasteur Inc